EP 1073632 A1 20010207 - SUBSTITUTED BENZAMIDES, THEIR PRODUCTION AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS
Title (en)
SUBSTITUTED BENZAMIDES, THEIR PRODUCTION AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS
Title (de)
SUBSTITUIERTE BENZAMIDE,DEREN HERSTELLUNG UND ANWENDUNG ALS INHIBITOREN VON CYSTEIN-PROTEASEN
Title (fr)
BENZAMIDES SUBSTITUES, LEUR PRODUCTION ET LEUR UTILISATION COMME INHIBITEURS DE PROTEASES DE CYSTEINE
Publication
Application
Priority
- DE 19817461 A 19980420
- EP 9902617 W 19990419
Abstract (en)
[origin: US6436925B1] Benzamides of the formula Iand its tautomeric forms, possible enantiomeric and diastereomeric forms, E and Z forms, and possible physiologically tolerated salts, in which the variables have the following meanings:R1-C1-C6-alkyl, branched or unbranched, where one of the C atoms in this chain may be substituted by a phenyl ring, cyclohexyl ring, indolyl ring and an SCH3 group, and the phenyl ring in turn is substituted by by [sic] a maximum of two R4 radicals, where R4 [lacuna] hydrogen, C1-C4-alkyl, branched or unbranched, -O-C1-C4-alkyl, OH, Cl, F, Br, I, CF3, NO2, NH2, CN, COOH, COO-C1-C4-alkyl, NHCO-C1-C4-alkyl, andR2 can be NR5CO-R6 and NHR5SO2-R6, andR3 is chlorine, bromine, fluorine, C1-C6-alkyl, NHCO-C1-C4-alkyl, NHSO2-C1-C4-alkyl, NO2, -O-C1-C4-alkyl, CN, COOH, CONH2, COO-C1-C4-alkyl, SO2-C1-C4-alkyl, -SO2Ph, SO2NH-C1-C4-alkyl, iodine, SO2NH2 and NH2, andA can be aromatic rings and heteroaromatic rings such as naphthyl, quinolyl, quinoxyl, benzimidazolyl, benzothienyl, quinazolyl, phenyl, thienyl, imidazolyl, pyridyl, pyrimidyl and pyridazyl, it also being possible for the rings to be substituted by by [sic] R9 and up to 2 R8 radicals, andB a bond, -(CH2)m-, -(CH2)m-O-(CH2)o-, -(CH2)o-S-(CH2)m-, -(CH2)o-SO-(CH2)m-, -(CH2)o-SO2-(CH2)m-, -CH=CH-, -C=C-, -CO-CH=CH-, -(CH2)o-CO-(CH2)m-, -(CH2)m-NHCO-(CH2)o-, -(CH2)m-CONH-(CH2)o-, -(CH2)m-NHSO2-(CH2)o-, -NH-CO-CH=CH-, -(CH2)m-SO2NH-(CH2)o-,A-B together alsoR5 hydrogen and C1-C4-alkyl andR6 is hydrogen, phenyl, naphthyl, C1-C6-alkyl, linear or branched, it being possible for a C atom in the chain to be substituted by a phenyl ring which itself may also be substituted by one or two R4 radicals, andR8 can be hydrogen, C1-C4-alkyl, branched or unbranched, -O-C1-C4-alkyl, OH, Cl, F, Br, I, CF3, NO2, NH2, CN, COOH, COO-C1-C4-alkyl, -NHCO-C1-C4-alkyl, phenyl, NHCO-phenyl, -NHSO2-C1-C4-alkyl, -NHSO2-phenyl, -SO2-C1-C4-alkyl, pyridine [sic] and SO2-phenyl,R9 hydrogen, -CHR14-(CH2)p-R12 where R12 pyrrolidine [sic], morpholine [sic], piperidine [sic], hexahydroazepine [sic], homopiperazine [sic], and R10 [lacuna] C1-C6-alkyl, branched or unbranched, and which may also carry a phenyl ring which is in turn substituted by by [sic] a maximum of two R11 radicals, where R11 is hydrogen, C1-C4-alkyl, branched or unbranched, -O-C1-C4-alkyl, OH, Cl, F, Br, I, CF3, NO2, NH2, CN, COOH, COO-C1-C4-alkyl, NHCO-C1-C4-alkyl, -NHSO2-C1-C4-alkyl and -SO2-C1-C4-alkyl; andR13 is hydrogen and C1-C6-alkyl, branched or unbranched, andn,p is [sic], independently of one another, a number 0, 1 or 2, andm,o is [sic], independently of one another, a number 0, 1, 2, 3 or 4.
IPC 1-7
C07C 311/21; C07C 233/78; C07D 295/08; C07D 213/56; A61K 31/18; A61K 31/44
IPC 8 full level
A61K 31/18 (2006.01); A61K 31/27 (2006.01); A61K 31/4409 (2006.01); A61K 31/4418 (2006.01); A61P 9/00 (2006.01); A61P 13/12 (2006.01); C07D 295/08 (2006.01); A61P 25/00 (2006.01); A61P 25/08 (2006.01); A61P 25/14 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01); C07C 233/78 (2006.01); C07C 235/42 (2006.01); C07C 237/34 (2006.01); C07C 311/21 (2006.01); C07D 213/56 (2006.01); C07D 295/096 (2006.01)
CPC (source: EP KR US)
A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/08 (2018.01 - EP); A61P 25/14 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 35/04 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07C 233/78 (2013.01 - EP US); C07C 235/42 (2013.01 - EP US); C07C 237/34 (2013.01 - EP US); C07C 311/21 (2013.01 - EP KR US); C07D 213/56 (2013.01 - EP US); C07D 295/096 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
US 6436925 B1 20020820; AU 3818699 A 19991108; AU 743245 B2 20020124; BG 104856 A 20010531; BR 9909776 A 20001219; CA 2328430 A1 19991028; CN 1306509 A 20010801; CZ 20003890 A3 20011114; DE 19817461 A1 19991021; EP 1073632 A1 20010207; HR P20000777 A2 20010630; HU P0101616 A1 20010928; HU P0101616 A3 20021028; ID 26305 A 20001214; IL 138676 A0 20011031; JP 2002512220 A 20020423; KR 20010042837 A 20010525; NO 20005265 D0 20001019; NO 20005265 L 20001019; PL 343466 A1 20010813; SK 14122000 A3 20010510; TR 200003069 T2 20090121; WO 9954293 A1 19991028; ZA 200006758 B 20011212
DOCDB simple family (application)
US 64767300 A 20001003; AU 3818699 A 19990419; BG 10485600 A 20001013; BR 9909776 A 19990419; CA 2328430 A 19990419; CN 99807638 A 19990419; CZ 20003890 A 19990419; DE 19817461 A 19980420; EP 9902617 W 19990419; EP 99920704 A 19990419; HR P20000777 A 20001115; HU P0101616 A 19990419; ID 20002113 A 19990419; IL 13867699 A 19990419; JP 2000544634 A 19990419; KR 20007011601 A 20001019; NO 20005265 A 20001019; PL 34346699 A 19990419; SK 14122000 A 19990419; TR 200003069 T 19990419; ZA 200006758 A 20001120